Proxi Biotech, an early stage spin-off from Staten Serum Institute, has developed the BID Technology for detoxification of bacterial toxins to be used as next generation vaccine antigens. BID Technology replaces the conventional cross-reacting agents in the development of new antigens for toxoid-based vaccines that are highly needed to overcome the challenges of antimicrobial resistance.